The outer membranepermeability-increasing action of deacylpolymyxins was comparedto the well-known potent action of polymyxin B nonapeptide (PMBN). Deacylpolymyxin B (DAPB), prepared by treating polymyxin B with polymyxin acylase, was found to be a slightly more effective permeabilizer than PMBN. As low a DAPBconcentration as 1 /*g/ml sensitized Escherichia coli to the probe antibiotics (rifampin, fusidic acid, erythromycin, clindamycin, novobiocin) by factors 30~100 and Salmonella typhimurium by factors 10~100. A higher concentration (3 /Jg/ml) ofDAPB elicited further sensitization. Also deacylcolistin (DAC)was found to be an effective permeabilizer.
removed from polymyxin (PM) using ficin or papain to yield a PM-derived nonapeptide ( Fig. 1 ). This
PMnonapeptide lacks the bactericidal activity of the parent compound. It was then found by Vaara and Vaara3~5) and confirmed by others6~9), that PMnonapeptides still have one important property left, viz., they drastically damage the outermost cell wall structure (the outer membrane: OM) of
Gram-negative bacteria and increase its permeability to hydrophobic antibiotics. However, it is not very clear, how selectively papain and ficin act in the hydrolysis of PM. In the light of the results of Chihara et al. (Table 7 in PMacylase is a new enzyme, recently reported by Kimura and co-workers, and deacylates PMand many other N-acyl compoundsll~13). It removes only the fatty acyl group of PMand leaves the peptide moiety completely intact (Fig. 1) .
In this study, we have compared the cell wall permeability-increasing potency of PMB nohapeptide (PMBN)and deacyl PMs. We will show that deacylpolymyxins are at least as effective permeabilizers as PMBN.
Materials and Methods

Bacterial Strains
Smooth Escherichia coli IH3080 (O18 : K1 : H8) and rough Salmonella typhimurium SH5014 (LPS chemotype Rb2) are strains used in our earlier permeability studies4'14~17>.
PMBNSulfate
PMBNwas prepared essentially as described by Viljanen and Vaara14) and was a kind gift from Farmos Group Ltd. (Turku, Finland). Its residual content of PMB was approx 0.1%, as determined by reversed-phase HPLC10).
Deacylcolistin (DAC) Sulfate
DACsulfate was prepared from colistin sulfate (a kind gift from BanyuPharmaceutical Co., Ltd., Tokyo, Japan) by using PMacylase (acetone-dried cell powder of Pseudomonas M-6-3 strain) as described previously1 1}.
Preparation of Deacylpolymyxin B (DAPB) Sulfate PMB sulfate, 2g (Sigma Chemical Co., U.S.A.) was dissolved in 200ml of deionized water and the solution was adjusted to pH 7.5 with 1 N NaOH.400 mg ofacetone-dried cell powder ofPseudomonas M-6-3 (the source of PMacylase, see ref ll) was added. The mixture was shaken at 37°C for 48 hours. Small samples were withdrawn at intervals to monitor the pH and the liberated fatty acids. Whenthe pH dropped, it was raised to 7.5 with 0.1 n NaOH.After centrifugation (10,000 x g, 30 minutes, to remove the insoluble mass that formed), the pH of the supernatant was lowered to 2 with 1 n H2SO4,and the supernatant was washed with ether to remove free fatty acids. The water layer was adjusted to pH4.0 with 1 n NaOHand was coned in vacuo to approx 4ml, applied on a Sephadex G-15 column (90 x 1.6cm, i.d., Pharmacia LKB, Uppsala, Sweden), and eluted with water. Fractions were analyzed by TLC and ninhydrin staining for the presence of DAPB, and the DAPB-containing fractions were concentrated. DAPBwas further purified by HPLCby using a YMC-Pack SH-343 column (25 x 2cm i.d., particle size: 10fim, Yamamura Chemical Institute, Kyoto, Japan), isocratic elution with 0.01 N H2SO4 in acetonitrile -water (1 5 : 85), the flow rate of 6 ml/minute, and a variable-wavelength UVdetector (875-UV, Japan Spectroscopic, Tokyo, Japan; set at 220 nm). The DAPB-containing fractions were collected and adjusted to pH 4 with saturated Ba(OH)2 solution. After the precipitate formed was removed by centrifugation (10,000 x g, 30 minutes), the supernatant was lyophilized, yielding 800 mg of DAPBsulfate as white powder.
Purity Analysis of DAPBSulfate Purity analysis was performed using an analytical column YMC-Pack ODSAM-312 (150 x 6mm, i.d.), elution with 0.1m NaCl-HCl (pH 2.0)-MeOH (45:55), the flow rare of 1.0ml/minute, and the detection at 210 nm.
AmmoAcid Analysis of the DAPBPreparation One mg of DAPBsulfate was hydrolyzed with 0.5 ml of constant-boiling hydrochloric acid at 1 10°C for 18 hours, the hydrolysate was then analyzed with a Hitachi L-8500 automatic amino acid analyzer.
FABMass Spectra FABmass spectra were obtained from a glycerol matrix with a JMS-DX 303 mass spectrometer (Nippon Densi, Tokyo, Japan).
GC of the Fatty Acids Liberated from PMB The ether fraction (see above) was analyzed for the presence of PMB-derived fatty acids. Ether was removed by distillation, and the residue (approx 100 mg) was esterified with MeOH-BF3and analyzed in GCusing the following conditions: a OV-1 column (2.1 m x 3.2mm, i.d.), the flow rate of 50ml/minute for the carrier gas, a FID-detector.
Antibiotics
Rifampin, fusidic acid (sodium salt) and novobiocin (sodium salt) were from Sigma, erythromycin ethylsuccinate from Orion (Helsinki, Finland), and clindamycin hydrochloride from Upjohn (Kalamazoo, U.S.A.).
The stock solution of rifampin was prepared by dissolving lOmg of rifampin with 1 ml of MeOH, after which deionized water was added to a final volume of 10ml. The stock solution of erythromycin was prepared by dissolving 10mg with 4ml of 96% EtOH, after which deionized water was added to a final volume of 10ml.
Synergistic Growth Inhibition Assay
This was done essentially as in ref 17 by using the checkerboard technique, microdilution plates, L broth as the assay medium,and bacterial inoculum size of 10* cells per ml. After an incubation time of 18 hours at 37°C, the growth (^405) of each well was measured with a Titertek Multiscan spectrophotometer (Labsystems, Helsinki, Finland). Before the reading, the spectrophotometer was blanked with corresponding uninoculated, drug-containing media. The MICof an antibotic was defined as the lowest concentration of the antibiotic which reduced the growth of the target becteria by > 95%.
Results
Preparation
of DAPB DAPBwas prepared using PMacylase and the methodology previously described for the preparation of deacylcolistinU). Aminoacid composition of the product (A2bu, Thr, Leu, and Phe in a molar ratio of6.5 : 1.8 : 1.0 : 0.9) corresponded to that expected for DAPB. Furthermore, in MS (Fig. 2) , the protonated Intrinsic Antibacterial Activities of the Compounds The intrinsic antibacterial activities of the compoundsare shownin Table 1 . As shownearlier, PMBN virtually lacks the direct antibacterial activity4'5'14*, and no inhibition of the growth of E. coli or S. typhimurium was observed whenPMBNconcentrations up to 300^g/ml were tested. In contrast to PMBN, both DAPBand DAChad a measurable inhibitory action (MICs 10~30/jg/ml). Because the deacyl preparations contain no detectable amounts of residual PM,it is rather unlikely that the growth inhibition was due to contaminating PM.
Permeability-increasing Action Rifampin, fusidic acid, erythromycin, clindamycin, and novobiocin are typical representatives of the large group of hydrophobic antibacterial agents against which the OMof Gram-negative cell wall is known to be an effective permeability barrier15~18). These antibiotics do not effectively permeate the intact OM of Gram-negative enteric bacteria but cross the OMof certain OM-defective mutants as well as the OM damagedby chelators or polycations. Accordingly, these five antibiotics were chosen to be probes to detect the OMpermeability increase induced by the PMderivatives. Furthermore, instead of exceedingly artificial assay media of low ionic strength19~21), see also22), an isotonic NaCl-containing bacterial growth medium (L broth) was used. The results are shown in Tables 2 and 3 . As low a DAPBconcentration as 1 /xg/ml sensitized E. coli to the probe antibiotics by a factor of approximately 30~100. S. typhimurium was sensitized by a factor of 10~100. A higher concentration of DAPB(3 /ig/ml) elicited further sensitization. Also DACwas active. PMBNwas clearly and reproducibly somewhat less active than DAPB.
The effective synergism between the hydrophobic antibiotics and all the PMderivatives is also evident in Fig. 4 where the growth of target bacteria is shown as absorbance readings. The results of Fig. 4 indicate After the incubation of 18 hours at 37°C, the growth was measured (in a multichannel spectrophotometer) and was related to the value 100 (representing the growth in the absence of any antibiotics and PMderivatives).
for instance that 0.1^g of rifampin per ml was sufficient to inhibit by 97% the growth of E. coli when 1 /ig of DAPBper ml was present, while, in the absence of DAPB,a 100-fold higher concentration of rifampin was required for the sameeffect.
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Discussion
Agents which increase the permeability of enterobacterial OMto antibiotics and other inhibitors could be expected to be potentially useful in antibacterial therapy. PMs have a high affinity for the lipopolysaccharide constituent of the OM23)24). As reviewed in introduction, the fatty acyl A2bu-lacking PMderivatives (nonapeptides) are effective permeabilizers of the OM.'Furthermore, the animal toxicity of PMnonapeptides is significantly lower than that of their parent compounds2'25~27). This communication indicates that deacylpolymyxins (PM decapeptides) are also potent OMpermeability-increasing agents.
DAPBappears to be slightly more active than PMBNas a permeabilizer. In contrast to PMBN, high concentrations of deacylpolymyxins are also directly antibacterial. Due to PMdeacylase, which has recently been described by Kimura et a/.11*, deacylpolymyxins are easier to prepare and purify than PM nonapeptides and, accordingly, they might be more useful. It would be interesting to compare the toxicity profile of deacylpolymyxins with those of PMsand their nonapeptides.
